2.43
+0.01(+0.41%)
Currency In USD
| Previous Close | 2.42 |
| Open | 2.46 |
| Day High | 2.46 |
| Day Low | 2.41 |
| 52-Week High | 6.2 |
| 52-Week Low | 1.33 |
| Volume | 12,997 |
| Average Volume | 70,724 |
| Market Cap | 23.97M |
| PE | -2.31 |
| EPS | -1.05 |
| Moving Average 50 Days | 2.52 |
| Moving Average 200 Days | 2.45 |
| Change | 0.01 |
NeurAxis to Host Second Quarter 2025 Results and Business Update Call on Tuesday, August 12, 2025
GlobeNewswire Inc.
Aug 05, 2025 12:30 PM GMT
Financial results to be released before market open; Conference call to be conducted at 9:00 a.m. Eastern TimeCARMEL, Ind., Aug. 05, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology
NeurAxis Announces New Medical Policy Coverage with Two Health Insurers, Adding 700,000 Covered Lives
GlobeNewswire Inc.
Jun 17, 2025 12:00 PM GMT
CARMEL, Ind., June 17, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children a
NeurAxis Achieves Critical Milestone; Secures Key Academic Society Guidelines Recommendation for Treatment of Functional Abdominal Pain (FAP) in IBS
GlobeNewswire Inc.
Jun 10, 2025 12:00 PM GMT
Practice guidelines published in the Journal of Pediatric Gastroenterology & Nutrition (JPGN) name Percutaneous Electrical Nerve Field Stimulation (PENFS) as a recommended treatment option for FAP in IBSNeurAxis’s PENFS technology is the only FDA-cle